Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark one)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number 000-05576

DOMINARI HOLDINGS INC.

(Exact name of registrant as specified in its charter)

Delaware		52-0849320
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

725 5^th Avenue, 22^nd Floor, New York, NY 10022

(Address of Principal Executive Offices, including zip code)

(703) 992-9325

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files.) Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	☐	Accelerated Filer	☐
Non-accelerated Filer	☒	Smaller Reporting Company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		DOMH		The Nasdaq Capital Market LLC

As of August 8, 2023, there were 5,345,312 shares of the Company’s common stock issued and outstanding.

DOMINARI HOLDINGS INC.

Form 10-Q

For the Quarter Ended June 30, 2023

Index

		Page No.

Part I. Financial Information

Item 1.	Financial Statements (Unaudited)	1

	Condensed Consolidated Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022	1

	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022 (Unaudited)	2

	Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity for the three and six months ended June 30, 2023 and 2022 (Unaudited)	3

	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022 (Unaudited)	5

	Notes to the Condensed Consolidated Financial Statements (Unaudited)	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24

Item 4.	Controls and Procedures	24

Part II. Other Information

Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3.	Defaults Upon Senior Securities	25

Item 4.	Mine Safety Disclosures	25

Item 5.	Other Information	25

Item 6.	Exhibits	25

Signatures		26

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

DOMINARI HOLDINGS INC.

Condensed Consolidated Balance Sheets

($ in thousands except share and per share amounts)

	June 30,			December 31,
	2023			2022
	(Unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	3,598		$	33,174
Marketable securities		20,675			7,130
Deposits with clearing broker		7,082			-
Prepaid expenses and other assets		715			564
Prepaid acquisition cost		-			301
Short-term investments, at fair value		13			13
Notes receivable, at fair value - current portion		6,339			7,474
Investment in Fieldpoint Securities		-			2,000
Total current assets		38,422			50,656

Property and equipment, net		387			-
Notes receivable, at fair value - non-current portion		1,622			1,100
Employee forgivable loan receivable		98			-
Investments		23,178			23,103
Right-of-use assets		3,530			919
Security deposit		458			458
Total assets	$	67,695		$	76,236

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued expenses	$	232		$	447
Accrued salaries and benefits		632			1,260
Income taxes withheld		1,300			-
Accrued Commissions		17			-
Lease liability - current		353			82
Other Current liability		124			-
Total current liabilities		2,658			1,789

Lease liability		3,259			680
Total liabilities		5,917			2,469

Stockholders’ equity
Preferred stock, $.0001 par value, 50,000,000 Authorized
Series D: 5,000,000 shares designated; 3,825 shares issued and outstanding at June 30, 2023 and December 31, 2022; liquidation value of $0.0001 per share		-			-
Series D-1: 5,000,000 shares designated; 834 shares issued and outstanding at June 30, 2023 and December 31, 2022; liquidation value of $0.0001 per share		-			-
Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,345,312 and 5,485,096 shares issued at June 30, 2023 and December 31, 2022, respectively; 5,285,164 and 5,017,079 shares outstanding at June 30, 2023 and December 31, 2022, respectively		-			-
Additional paid-in capital		260,585			262,970
Treasury stock, at cost, 60,148 and 468,017 shares at June 30, 2023 and December 31, 2022, respectively		(501	)		(3,322	)
Accumulated deficit		(198,306	)		(185,881	)
Total stockholders’ equity		61,778			73,767
Total liabilities and stockholders’ equity	$	67,695		$	76,236

See accompanying notes to unaudited condensed consolidated financial statements.

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Operations

($ in thousands except share and per share amounts)

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Revenues	$	71		$	-		$	71		$	-

Operating costs and expenses
General and administrative	$	9,080		$	2,262		$	12,913		$	4,049
Research and development		2			36			3			2,052
Total operating expenses		9,082			2,298			12,916			6,101
Loss from operations		(9,011	)		(2,298	)		(12,845	)		(6,101	)

Other income (expenses)
Other income		-			-			-			64
Interest income		160			220			297			399
Gain (loss) on marketable securities		400			(2,239	)		335			(2,736	)
Unrealized loss on note receivable		(212	)		-			(212	)		-
Change in fair value of investments		-			(760	)		-			(238	)
Total other income (expenses)		348			(2,779	)		420			(2,511	)
Net loss	$	(8,663	)	$	(5,077	)	$	(12,425	)	$	(8,612	)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock		-			(1,100	)		-			(4,109	)
Net Loss Attributable to Common Shareholders	$	(8,663	)	$	(6,177	)	$	(12,425	)	$	(12,721	)

Net loss per share, basic and diluted
Basic and Diluted	$	(1.79	)	$	(1.18	)	$	(2.45	)	$	(2.42	)

Weighted average number of shares outstanding, basic and diluted
Basic and Diluted		4,827,239			5,251,023			5,065,055			5,251,766

See accompanying notes to unaudited condensed consolidated financial statements.

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity

($ in thousands except share and per share amounts)

(Unaudited)

For the Three Months Ended June 30, 2023 and 2022

	Preferred Stock				Common Stock				Additional Paid-in		Treasury Stock					Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital		Shares		Amount			Deficit			Equity
Balance at March 31, 2023		4,659	$	-		4,815,597	$	-	$	259,215		60,148	$	(501	)	$	(189,643	)	$	69,071
Stock-based compensation		-		-		529,715		-		1,370		-		-			-			1,370
Net loss		-		-		-		-		-		-		-			(8,663	)		(8,663	)
Balance at June 30, 2023		4,659	$	-		5,345,312	$	-	$	260,585		60,148	$	(501	)	$	(198,306	)	$	61,778

	Redeemable Convertible Preferred Stock																		Preferred				Additional											Total
	Series O						Series P							Common Stock					Stock				Paid-in			Treasury Stock					Accumulated			Stockholders’
	Shares			Amount			Shares				Amount			Shares			Amount		Shares		Amount		Capital			Shares		Amount			Deficit			Equity
Balance at March 31, 2022		11,000		$	11,000			11,000		$		11,000			5,252,517		$	-		4,659	$	-	$	262,624			-	$	(264	)	$	(167,309	)	$	95,051
Redemption of Series O Redeemable Convertible Preferred Stock		(11,000	)		(11,000	)		-				-			-			-		-		-		-			-		-			-			-
Redemption of Series P Redeemable Convertible Preferred Stock		-			-			(11,000	)			(11,000	)		-			-		-		-		-			-		-			-			-
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock		-			-			-				-			-			-		-		-		(1,100	)		-		-			-			(1,100	)
Repurchase of treasury stock		-			-			-				-			-			-		-		-		-			242,902		(1,486	)					(1,486	)
Stock-based compensation		-			-			-				-			-			-		-		-		105			-		-			-			105
Fractional shares adjusted for reverse split		-			-			-				-			(5,665	)		-		-		-		(26	)		-		-			-			(26	)
Net loss		-			-			-				-			-			-		-		-		-			-		-			(5,077	)		(5,077	)
Balance at June 30, 2022		-		$	-			-			$	-			5,246,852		$	-		4,659	$	-	$	261,603			242,902	$	(1,750	)	$	(172,386	)	$	87,467

For the Six Months Ended June 30, 2023 and 2022

	Preferred Stock				Common Stock					Additional Paid-in			Treasury Stock						Accumulated			Total Stockholders’
	Shares		Amount		Shares			Amount		Capital			Shares			Amount			Deficit			Equity
Balance at December 31, 2022		4,659	$	-		5,485,096		$	-	$	262,970			468,017		$	(3,322	)	$	(185,881	)	$	73,767
Stock-based compensation		-		-		529,715			-		1,375			-			-			-			1,375
Cancellation of common stock		-		-		(25,000	)		-		-			-			-			-			-
Purchase of treasury stock		-		-		-			-		-			236,630			(939	)		-			(939	)
Retirement of treasury stock		-		-		(644,499	)		-		(3,760	)		(644,499	)		3,760			-			-
Net loss		-		-		-			-		-			-			-			(12,425	)		(12,425	)
Balance at June 30, 2023		4,659	$	-		5,345,312		$	-	$	260,585			60,148		$	(501	)	$	(198,306	)	$	61,778

	Redeemable Convertible Preferred Stock																	Preferred				Additional											Total
	Series O						Series P						Common Stock					Stock				Paid-in			Treasury Stock					Accumulated			Stockholders’
	Shares			Amount			Shares			Amount			Shares			Amount		Shares		Amount		Capital			Shares		Amount			Deficit			Equity
Balance at December 31, 2021		-		$	-			-		$	-			5,275,329		$	-		4,659	$	-	$	265,633			-	$	(264	)	$	(163,774	)	$	101,595
Issuance of Series O redeemable convertible preferred stock for cash		11,000			11,000									-			-		-		-		-			-		-			-			-
Issuance of Series P redeemable convertible preferred stock for cash								11,000			11,000			-			-		-		-		-			-		-			-			-
Cost on issuance of Series O and Series P Redeemable Convertible Preferred Stock		-			(1,504	)		-			(1,505	)		-			-		-		-		-			-		-			-			-
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock		-			1,504			-			1,505			-			-		-		-		(4,109	)		-		-			-			(4,109	)
Redemption of Series O Redeemable Convertible Preferred Stock		(11,000	)		(11,000	)		-			-			-			-		-		-		-			-		-			-			-
Redemption of Series P Redeemable Convertible Preferred Stock		-			-			(11,000	)		(11,000	)		-			-		-		-		-			-		-			-			-
Repurchase of treasury stock		-			-			-			-			-			-		-		-		-			242,902		(1,486	)		-			(1,486	)
Stock-based compensation		-			-			-			-			-			-		-		-		105			-		-			-			105
Cancellation of common stock related to investment in CBM		-			-			-			-			(22,812	)		-		-		-		-			-		-			-			-
Fractional shares adjusted for reverse split		-			-			-			-			(5,665	)		-		-		-		(26	)		-		-			-			(26	)
Net loss		-			-			-			-			-			-		-		-		-			-		-			(8,612	)		(8,612	)
Balance at June 30, 2022		-		$	-			-		$	-			5,246,852		$	-		4,659	$	-	$	261,603			242,902	$	(1,750	)	$	(172,386	)	$	87,467

See accompanying notes to unaudited condensed consolidated financial statements.

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Cash Flows

($ in thousands)

(Unaudited)

	Six Months Ended June 30,
	2023			2022
Cash flows from operating activities
Net loss	$	(12,425	)	$	(8,612	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of right-of-use assets		182			-
Depreciation		32			-
Change in fair value of short-term investment		-			1,646
Change in fair value of long-term investment		-			(1,408	)
Stock-based compensation		2,675			105
Realized loss on marketable securities		487			568
Unrealized (gain) loss on marketable securities		(514	)		2,299
Unrealized loss on note receivable		212			-
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(229	)		153
Prepaid acquisition cost		301			-
Deposits with clearing broker		(3,532	)		-
Accounts payable and accrued expenses		(428	)		(239	)
Accrued salaries and benefits		(628	)		7
Accrued commissions		(8	)		-
Lease liabilities		58			-
Other current liabilities		3			-
Notes receivable, at fair value – net interest accrued		(99	)		(377	)
Deposit		-			8
Net cash used in operating activities		(13,913	)		(5,850	)

Cash flows from investing activities
Purchase of marketable securities		(34,014	)		(27,460	)
Sale of marketable securities		20,494			28,272
Proceeds from sale of digital currencies		-			93
Purchase of fixed assets		(419	)		-
Acquisition of FPS, net of cash acquired and receivable owed from FPS		(1,112	)		-
Collection of principal on note receivable		502			-
Funds to employee forgivable loan		(100	)		-
Purchase of short-term and long-term investments		(75	)		(14,605	)
Purchase of short-term and long-term promissory notes		-			(1,600	)
Net cash used in investing activities		(14,724	)		(15,300	)

Cash flows from financing activities
Proceeds from issuance of Series O and Series P Redeemable Convertible Preferred Stock, net of discount and offering cost		-			17,891
Payment for fractional shares		-			(26	)
Redemption of Series O and Series P Redeemable Convertible Preferred Stock		-			(22,000	)
Purchase of treasury stock		(939	)		(1,486	)
Net cash used in financing activities		(939	)		(5,621	)

Net decrease in cash and cash equivalents and restricted cash		(29,576	)		(26,771	)
Cash and cash equivalents, beginning of period		33,174			65,562
Cash and cash equivalents, end of period	$	3,598		$	38,791

Non-cash investing and financing activities
Transfer from short-term investment to marketable securities	$	-		$	1,482
Reclassify from convertible note receivable to notes receivable at fair value	$	-		$	2,147
Promissory convertible note receivable conversion into common shares	$	-		$	1,508

On March 27, 2023, the Company acquired all assets and liabilities of FPS as disclosed in Note 4:
Net assets acquired, net of cash acquired and receivable owed from FPS	$	3,112
Less - Deposit previously transferred in October 2022 to FPS	$	(2,000	)
Net cash paid	$	1,112

See accompanying notes to unaudited condensed consolidated financial statements.

DOMINARI HOLDINGS INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1. Organization and Description of Business and Recent Developments

Organization and Description of Business

Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.

Additionally, AIkido Labs, LLC (“Aikido Labs”), another wholly owned subsidiary of the Company, is in the process of winding down its historical pipeline of biotechnology assets consisting of patented technologies from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. Aikido Labs has historically explored opportunities in high growth industries and has equity holdings including Anduril Industries, Inc, Databricks, Inc., Discord, Inc., Epic Games, Inc., Payward, Inc. dba Kraken, Space Exploration Technologies Corp. dba SpaceX, Tevva Motors Ltd., Thrasio, LLC, and Yanka Industries, Inc. dba Masterclass.

Note 2. Liquidity and Capital Resources

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.

Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

Note 3. Summary of Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2022 Annual Report other than those discussed below.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

Results for interim periods are not necessarily indicative of results to be expected for a full year or any future period.

Use of Estimates

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

Deposits with clearing broker

Deposits with Dominari Securities’ clearing broker consisted of approximately $7.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of June 30, 2023.

Leases

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 10 - Leases).

Revenue

The Company recognizes revenues under ASC 606 - Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:

●

Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.

●

Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.

Recently adopted accounting standards

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.

Effect of new accounting pronouncements not yet adopted

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03.

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.

Effect of new accounting pronouncements to be adopted in future periods

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

Note 4. FPS Acquisition

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with FINRA and an investment adviser registered with the SEC (the “FPS Acquisition”). Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “FPS Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses were renamed and will operate as Dominari Securities, a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial of 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing (the “Second Closing”) occurred on March 27, 2023. Dominari Financial paid to the Seller an additional approximate $1.6 million consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the FPS Membership Interests.

Consideration Transferred

The FPS Acquisition was accounted for as a business combination under ASC 805.

Under the terms of the FPS Purchase Agreement and subsequent Amendments and Side Letters, 100% of the FPS Membership Interests were acquired for cash consideration of approximately $3.4 million, which reflected the fair value of net assets acquired, plus a $1 purchase price. At March 31, 2023, Dominari Financial had not finalized the purchase accounting related to the fair value of assets acquired in the FPS Acquisition. Pursuant to the Initial Closing and Second Closing, Dominari Financial had wired a total of approximately $3.6 million in cash to the Seller. The purchase price allocation identified net assets of approximately $3.4 million, resulting in a receivable due from the Seller for approximately $0.2 million. The receivable is not included within the consideration transferred as part of the FPS Acquisition but is included within prepaid expenses and other assets within the unaudited condensed consolidated balance sheet as of March 31, 2023.

Under the acquisition method of accounting, the assets acquired, and liabilities assumed of FPS were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred approximately $0.3 million of transaction costs associated with the FPS Acquisition. The transaction costs are included in general and administrative expenses in the unaudited condensed consolidated statement of operations.

Fair Value of Net Assets Acquired

The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition:

	March 27,
	2023
	(Unaudited)
ASSETS
Cash and cash equivalents	$	92
Deposits with Clearing Broker-Dealer		3,550
Other receivables		53
Prepaid and other current assets		89
Total assets acquired		3,784

Liabilities
Accrued expenses	$	273
Accrued commissions		25
Wealth management liabilities		62
Total liabilities assumed		360

Total net assets of FPS Acquisition		3,424

Dominari Securities reported a net loss of approximately $7.7 million for the three-months ended June 30, 2023. Revenue for the period ended June 30, 2023, was approximately $0.07 million. The net loss was primarily a result of approximately $5.4 million of bonus and employee compensation expense and professional services of approximately $0.9 million. The bonus and compensation expense and professional service fees related to establishing the operations of the broker-dealer and are included in the general and administrative expenses line item within the unaudited condensed consolidated statement of operations.

Note 5. Investments in Marketable Securities

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Realized loss	$	(432	)	$	(344	)	$	(487	)	$	(568	)
Unrealized gain (loss)		643			(1,967	)		514			(2,299	)
Dividend income		188			72			308			131
Total	$	400		$	(2,239	)	$	335		$	(2,736	)

Note 6. Short-term investments

The following table presents the Company’s short-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):

	June 30, 2023		December 31, 2022
Investment in Vicinity Motor Corp.		13		13
Total		13		13

There was no change in the fair value of the short-term investments for the six months ended June 30, 2023.

The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:

	June 30, 2023			December 31, 2022
Option term (in years)		1.3			1.8
Volatility		76.9	%		76.90	%
Risk-free interest rate		4.47	%		4.47	%
Expected dividends		0.00	%		0.00	%
Stock price	$	0.96		$	0.96

Note 7. Long-Term Investments

The Company holds interests in several privately held companies as long-term investments that the Company perceives as potential IPO candidates. The following table presents the Company’s long-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):

	Cost Basis		June 30, 2023		December 31, 2022
Investment in Kerna Health Inc	$	2,140	$	4,940	$	4,940
Investment in Kaya Now		1,500		-		-
Investment in Tevva Motors		1,972		2,794		2,794
Investment in ASP Isotopes		1,300		-		-
Investment in AerocarveUS Corporation		1,075		1,075		1,000
Investment in Qxpress		1,000		1,000		1,000
Investment in Masterclass		170		170		170
Investment in Kraken		597		597		597
Investment in Epic Games		3,500		3,500		3,500
Investment in Tesspay		1,240		2,500		2,500
Investment in SpaceX		3,500		3,674		3,674
Investment in Databricks		1,200		1,200		1,200
Investment in Discord		476		476		476
Investment in Thrasio		300		300		300
Investment in Automation Anywhere		476		476		476
Investment in Anduril		476		476		476
Total	$	20,922	$	23,178	$	23,103

Investment in AerocarveUS Corporation

On November 22, 2021, the Company entered into an agreement (the “AerocarveUS Agreement”) with AerocarveUS Corporation, (“AerocarveUS”). Under the AerocarveUS Agreement, the Company agreed to purchase 250,000 shares of common stock of AerocarveUS for $1.0 million. AerocarveUS changed its name to “Unusual Machines, Inc.” on July 5, 2022. In March of 2023, the Company was issued an additional 64,377 shares at no cost. In June 2023, the Company purchased an additional 150,000 shares of common stock for approximately $0.08 million. The investment in AerocarveUS Corporation (a.k.a. Unusual Machines, Inc.) was valued at approximately $1.08 million as of June 30, 2023.

Note 8. Notes Receivable

The following table presents the Company’s notes receivable as of June 30, 2023 ($ in thousands):

	Maturity Date	Stated Interest Rate			Principal Amount		Interest Receivable		Fair Value
Notes receivable, at fair value
Convergent convertible note - current	01/29/2023		8	%	$	1,000	$	199	$	1,199
Convergent convertible note - non-current	01/29/2023		8	%	$	500	$	-	$	500
Raefan Industries LLC Investment	12/31/2023		8	%	$	4,518	$	623	$	5,141
American Innovative Robotics Investment	04/01/2027		8	%	$	1,100	$	22	$	1,122

Notes receivable, at fair value - current portion									$	6,339

Notes receivable, at fair value - non-current portion									$	1,622

Convergent Therapeutics, Inc. Investment

The Company’s 8% convertible promissory note (“Convergent Convertible Note”) issued by Convergent Therapeutics, Inc. (“Convergent”) in the principal amount of approximately $1.8 million pursuant to a Note Purchase Agreement matured on January 29, 2023. Upon maturity, Convergent entered into a contractual repayment schedule with the Company. Pursuant to the schedule, Convergent will make a total of eight payments in the amount of $250 thousand and accrued interest, every three months until fully satisfied.

The principal balance of the Convergent Convertible Note was approximately $1.8 million as of June 30, 2023. The Company recorded principal repayment of $0.5 million and interest income of approximately $0.1 million on the Convergent Convertible Note for the six months ended June 30, 2023.

Raefan Industries LLC Investment

The Company recorded an interest income receivable of approximately $0.6 million on the Raefan Industries Promissory Note as of June 30, 2023 and an unrealized loss on the note of approximately $0.2 million.

American Innovative Robotics, LLC Investment

The Company recorded interest income of approximately $44,000 on the Robotics Promissory Note for the six months ended June 30, 2023.

Kaya Now Inc. Investment

During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya’s business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of $0.5 million in the fourth quarter of 2022. The impairment charge represents an impairment loss of the total investment held as a promissory note resulting in a $0 balance for the Kaya Now Promissory Note as of June 30, 2023.

The Company received and recorded interest income related to the Kaya Now Promissory Note of approximately $10,000 for the six months ended June 30, 2023.

Note 9. Fair Value of Financial Assets and Liabilities

Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

The Company uses three levels of inputs that may be used to measure fair value:

Level 1 - quoted prices in active markets for identical assets or liabilities

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2023, and December 31, 2022 ($ in thousands):

	Fair value measured as of June 30, 2023
	Total at June 30,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2023		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities:
Equities	$	20,675	$	20,675	$	-	$	-
Total marketable securities	$	20,675	$	20,675	$	-	$	-
Short-term investment	$	13	$	-	$	-	$	13
Notes receivable at fair value, current portion	$	6,339	$	-	$	-	$	6,339
Notes receivable at fair value, non-current portion	$	1,622	$	-	$	-	$	1,622

	Fair value measured as of December 31, 2022
	Total at December 31,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities:
Equities	$	7,130	$	7,130	$	-	$	-
Total marketable securities	$	7,130	$	7,130	$	-	$	-
Short-term investment	$	13	$	-	$	-	$	13
Notes receivable at fair value, current portion	$	7,474	$	-	$	-	$	7,474
Notes receivable at fair value, non-current portion	$	1,100	$	-	$	-	$	1,100

Level 3 Measurement

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

Short-term investment at December 31, 2022	$	13
Short-term investment at June 30, 2023	$	13

Notes receivable at fair value, current portion at December 31, 2022	$	7,474
Collection of principal outstanding		(500	)
Note receivable, Convergent Therapeutics, non-current portion		(500	)
Unrealized loss on note receivable		(212	)
Accrued interest receivable		77
Notes receivable at fair value, current portion at June 30, 2023	$	6,339

Notes receivable at fair value, non-current portion at December 31, 2022	$	1,100
Note receivable, Convergent Therapeutics, non-current portion		500
Accrued interest receivable		22
Notes receivable at fair value, non-current portion at June 30, 2023	$	1,622

Note Receivable at fair value

As of June 30, 2023, the fair value of the notes receivable was measured taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No material change was noted in the fair value of the notes receivable during the three months ended June 30, 2023.

Note 10. Leases

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22^ndFloor Premises”). The Company currently uses the 22^nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22^nd Floor Premises on the Commencement Date.

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023.

The tables below represent the Company’s lease assets and liabilities as of June 30, 2023:

	June 30, 2023
Assets:
Operating lease right-of-use-assets	$	3,530

Liabilities:
Current
Operating		353
Long-term
Operating		3,259
	$	3,612

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

June 30,

2023

Weighted-average remaining lease term – operating leases (in years)

7.0

Weighted-average discount rate – operating leases

10.0

During the six months ended June 30, 2023, the Company recorded approximately $0.4 million of lease expense to current period operations.

	Three Months Ended		Six Months Ended
	June 30, 2023		June 30, 2023
Operating leases
Operating lease cost	$	179	$	313
Operating lease expense		179		313
Short-term lease rent expense		33		63
Net rent expense	$	212	$	376

Supplemental cash flow information related to leases were as follows:

	Six Months Ended
	June 30, 2023
Operating cash flows - operating leases	$	72
Right-of-use assets obtained in exchange for operating lease liabilities	$	2,796

As of June 30, 2023, future minimum payments during the next five years and thereafter are as follows:

	Operating
	Leases
Remaining Period Ended December 31, 2023	$	327
Year Ended December 31, 2024		750
Year Ended December 31, 2025		688
Year Ended December 31, 2026		688
Year Ended December 31, 2027		688
Year Ended December 31, 2028		770
Thereafter		1,166
Total		5,077
Less present value discount		(1,465	)
Operating lease liabilities	$	3,612

Note 11. Net Loss per Share

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2023, and 2022 are as follows:

	As of June 30,
	2023		2022
Convertible preferred stock		34		34
Warrants to purchase common stock		444,796		444,796
Options to purchase common stock		30,336		198,574
Total		475,166		643,404

Note 12. Stockholders’ Equity and Convertible Preferred Stock

Common Stock

On March 6, 2023, the Company cancelled 644,499 shares of common stock as a result of retirement of 644,499 shares of treasury stock.

On March 20, 2023, the Company cancelled 25,000 shares of common stock owned by a board member.

June 27, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,033,591 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $2.7 million. Pursuant to the Grant Agreement, the Company withheld 503,876 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the unaudited condensed consolidated balance sheet. See Restricted Stock roll-forward below.

Treasury Stock

On January 21, 2022, the Company’s board of directors authorized a share buyback program (the “Share Buyback Program”), pursuant to which the Company authorized the Share Buyback Program in an amount of up to three million dollars. During the six months ended June 30, 2023, the Company repurchased 236,630 shares at a cost of approximately $0.9 million or $3.97 per share through marketable securities account under the Share Buyback Program. The Company records treasury stock using the cost method.

On March 6, 2023, the Company retired 644,499 shares of treasury stock with original cost of approximately $3.8 million.

Warrants

A summary of warrant activity for the six months ended June 30, 2023, is presented below:

	Warrants		Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2022		444,796	$	29.25		-		3.20
Outstanding as of June 30, 2023		444,796	$	29.25		-		2.71

Restricted Stock Awards

A summary of restricted stock awards activity for the six months ended June 30, 2023, is presented below:

	Number of Restricted Stock Awards			Weighted Average Grant Day Fair Value
Nonvested at December 31, 2022		8,068		$	5.64
Granted		529,715		$	2.58
Vested		(537,783	)		2.63
Nonvested at June 30, 2023		-		$	-

As of June 30, 2023, there is no unrecognized stock-based compensation expense related to restricted stock awards.

Stock Options

A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2023 is presented below:

	Number of Shares			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2022		31,193		$	302.97	$	-		7.9
Employee options expired		(857	)	$	9,719.07
Outstanding as of June 30, 2023		30,336		$	36.97	$	-		7.6
Options vested and exercisable		26,578		$	41.35	$	-		7.5

Stock-based compensation associated with the amortization of stock option expense was approximately $8,000 and $0 for the six months ended June 30, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.

Estimated future stock-based compensation expense relating to unvested stock options is approximately $7,000.

Note 13. Revenue

The following table presents our total revenues disaggregated by revenue type for the three and six months ended June 30, 2023 and 2022 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2023			2022		2023		2022
Underwriting	$	43	$	-	$	43	$	-
Commissions		14		-		14		-
Other		14		-	$	14		-
Total	$	71	$	-	$	71	$	-

Note 14. Commitments and Contingencies

Legal Proceedings

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

Note 15. Regulatory

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of June 30, 2023, Dominari Securities had net capital of approximately $7.3 million, which was approximately $7.2 million in excess of required minimum net capital of $0.1 million.

Note 16. Related Party Transaction

In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, is also a member of the board of directors of Revere. The Company incurred fees of approximately $0.08 million and $0.6 million during the six months ending June 30, 2023, and 2022, respectively. These fees were included in general and administrative expense in the unaudited condensed consolidated statements of operations.

Note 17. Segment Reporting

The Company operates in two reportable business segments: (1) Dominari Securities and (2) Legacy AIkido Pharma. The Dominari Securities reportable business segment represents the Company’s broker-dealer business, which is composed of underwriting and transactional service activities. The Legacy AIkido Pharma reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido Pharma.

The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.” While assets are primarily held within the Legacy AIkido Pharma reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.

	Three Months Ended June 30, 2023
	Dominari Securities			Legacy AIkido Pharma			Consolidated
Revenue	$	71		$	-		$	71
Operating Costs
General and administrative		6,957			2,123		$	9,080
Research and development					2			2
Loss from operations	$	(6,886	)	$	(2,125	)	$	(9,011	)

Other (expenses) income
Other income								-
Interest income		44			116			160
Loss on marketable securities					400			400
Unrealized loss on note receivable					(212	)		(212	)
Total other (expenses) income	$	44		$	304		$	348
Net loss	$	(6,842	)	$	(1,821	)	$	(8,663	)

	Six Months Ended June 30, 2023
	Dominari Securities			Legacy AIkido Pharma			Consolidated
Revenue	$	71		$	-		$	71
Operating Costs
General and administrative		8,056			4,857			12,913
Research and development					3			3
Loss from operations	$	(7,985	)	$	(4,860	)	$	(12,845	)

Other (expenses) income
Other income					-			-
Interest income		44			253			297
Loss on marketable securities					335			335
Unrealized loss on note receivable					(212	)		(212	)
Total other (expenses) income	$	44		$	376		$	420
Net loss	$	(7,941	)	$	(4,484	)	$	(12,425	)

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

You should read this discussion together with the Financial Statements, related Notes and other financial information included elsewhere in this Form 10-Q. The following discussion contains assumptions, estimates and other forward-looking statements that involve a number of risks and uncertainties. These risks could cause our actual results to differ materially from those anticipated in these forward-looking statements. All references to “we,” “us,” “our” and the “Company” refer to Dominari Holdings Inc., a Delaware corporation and its consolidated subsidiaries unless the context requires otherwise.

Overview

Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (Dominari Securities), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.

Reverse Stock Split

On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock (the “Reverse Stock Split”). The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 20, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on June 2, 2022. The Reverse Stock Split was effective on June 7, 2022. All references to common stock, convertible preferred stock, warrants to purchase common stock, options to purchase common stock, restricted stock units, restricted stock awards, share data, per share data and related information contained in the unaudited condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to $26,000.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements. We have identified the accounting policies that we believe require application of management’s most subjective judgments, often requiring the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Our actual results may differ substantially from these estimates under different assumptions or conditions. There have been no significant changes to our critical accounting policies and estimates since December 31, 2022. The following represent those critical accounting policies that we believe most significantly impact the judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements.

Long-term investments

Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of financial assets and financial liabilities. In adopting this guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values.

For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of such equity investments through earnings when there is an observable transaction involving the same or a similar investment with the same issuer or upon an impairment.

Refer to Note 3 of the Annual Report for a discussion of all accounting policies.

Recently Issued Accounting Pronouncements

See Note 3 to the unaudited condensed consolidated financial statements for a discussion of recent accounting standards.

Results of Operations

Three Months Ended June 30, 2023, compared to the Three Months Ended June 30, 2022

During the three months ended June 30, 2023, we recognized approximately $0.07 million in revenue from operations, primarily driven by the underwriting revenue earned by Dominari Securities. During the three months ended June 30, 2023, and 2022, we incurred a loss from operations of approximately $9.0 million and $2.3 million, respectively. The consistent loss in operations year over year was primarily attributable to the following:

An approximate $6.8 million increase in general and administrative expenses – driven by approximately $0.02 million and $0.8 million of professional fees (legal, consulting, accounting, etc.) incurred to establish and operate Dominari Financial and Dominari Securities, respectively. In addition, the Company also incurred increased compensation expenses of approximately $6.3 million due to growing operations.

ii.

An approximate $0.03 million decrease in research and development expenses – attributable to the Company’s strategic business decision to transition away from the biotechnology industry and into financial services. The result is a decrease in research and development related expenses by almost 100%.

During the three months ended June 30, 2023 and 2022, other income (expenses) was approximately $0.3 million and $(2.8) million, respectively. The activity for the three months ended June 30, 2023 and 2022, is primarily a result of overall volatility in investment valuations due to macroeconomic uncertainty (i.e. inflation, global tensions in the Ukraine, etc.) impacting marketable securities and the change in fair value of short and long-term investments. Specifically:

Marketable securities – we recognized a gain of approximately $0.4 million for the three months ended June 30, 2023. The decrease of approximately $2.6 million in losses over prior year is a direct result of a decrease in unrealized losses of approximately $2.6 million and increase in dividend income of approximately $0.1 million, offset by an increase in realized loss of approximately $0.08 million. The decreases were driven by both market improvement and decrease in sale activity resulting in fewer realized losses.

ii.

Short-term and long-term investments –The changes over the three months ended June 30, 2023 and 2022 are a function of observable market transactions which resulted in a decrease in unrealized loss of approximately $0.8 million on the adjusted fair value of the investments during the three months ended June 30, 2023 and 2022, respectively.

Six Months Ended June 30, 2023, compared to the Six months ended June 30, 2022

During the six months ended June 30, 2023, we recognized approximately $0.07 million in revenue from operations, primarily driven by the underwriting revenue earned by Dominari Securities. During the six months ended June 30, 2023, and 2022, we incurred a loss from operations of approximately $12.8 million and $6.1 million, respectively. The consistent loss in operations year over year was primarily attributable to the following:

An approximate $8.9 million increase in general and administrative expenses – driven by approximately $0.1 million and $0.9 million of professional fees (legal, consulting, accounting, etc.) incurred to establish and operate Dominari Financial and Dominari Securities, respectively. In addition, the Company also incurred increased compensation expenses of approximately $6.3 million due to growing operations.

ii.

An approximate $2.0 million decrease in research and development expenses – attributable to the Company’s strategic business decision to transition away from the biotechnology industry and into financial services. The result is a decrease in research and development related expenses by almost 100%.

During the six months ended June 30, 2023 and 2022, other income (expenses) was approximately $0.4 million and $(2.5) million, respectively. The activity for the six months ended June 30, 2023 and 2022, is primarily a result of overall volatility in investment valuations due to macroeconomic uncertainty (i.e. inflation, global tensions in the Ukraine, etc.) impacting marketable securities and the change in fair value of short and long-term investments. Specifically:

Marketable securities – we recognized a gain of approximately $0.3 million for the six months ended June 30, 2023. The decrease of approximately $3.1 million in losses over prior year is a direct result of a decrease in unrealized losses of approximately $2.8 million and increase in dividend income of approximately $0.2 million, offset by an increase in realized loss of approximately $0.08 million. The decreases were driven by both market improvement and decrease in sale activity resulting in fewer realized losses.

ii.

Short-term and long-term investments –The changes over the six months ended June 30, 2023 and 2022 are a function of observable market transactions which resulted in a decrease in unrealized loss of approximately $0.2 million on the adjusted fair value of the investments during the six months ended June 30, 2023 and 2022, respectively.

Liquidity and Capital Resources

We continue to incur ongoing administrative and other expenses, including public company expenses. While we continue to implement our business strategy, we intend to finance our activities through:

●

managing current cash and cash equivalents on hand from our past debt and equity offerings;

●

seeking additional funds raised through the sale of additional securities in the future; and

●

seeking additional liquidity through credit facilities or other debt arrangements.

Our ultimate success is dependent on our ability to generate sufficient cash flow to meet our obligations on a timely basis. Our business may require significant amounts of capital to sustain operations that we need to execute our longer-term business plan to support our transition into the financial services industry. Our working capital amounted to approximately $35.7 million as of June 30, 2023. We believe our cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations will be sufficient to meet our working capital, and capital expenditure requirements for at least the next 12 months. In the event that cash flow from operations is not sufficient to fund our operations, as expected, or if our plans or assumptions change, including if inflation begins to have a greater impact on our business or if we decide to move forward with any activities that require more outlays of cash than originally planned, we may need to raise additional capital sooner than expected. We may raise this additional capital by obtaining additional debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly-traded company or from continuing operations.

Our ability to obtain capital to implement our growth strategy over the longer term will depend on our future operating performance, financial condition and, more broadly, on the availability of equity and debt financing. Capital availability will be affected by prevailing conditions in our industry, the global economy, the global financial markets, and other factors, many of which are beyond our control. Specifically, as a result of recent volatility and weakness in the public markets, due to, among other factors, uncertainty in the global economy and financial markets, it may be much more difficult to raise additional capital, if and when it is needed, unless the public markets become less volatile and stronger at such time that we seek to raise additional capital. In addition, any additional debt service requirements we take on could be based on higher interest rates and shorter maturities and could impose a significant burden on our results of operations and financial condition, and the issuance of additional equity securities could result in significant dilution to stockholders.

Cash Flows from Operating Activities

For the six months ended June 30, 2023 and 2022, net cash used in operations was approximately $13.9 million and $5.9 million, respectively. The cash used in operating activities for the six months ended June 30, 2023, is primarily attributable to a net loss of approximately $11.7 million, approximately $0.5 million of realized gain on marketable securities and changes in operating assets and liabilities of $4.6 million, partially offset by $2.7 million stock-based compensation expense and approximately $0.5 million in unrealized losses on marketable securities. The cash used in operating activities for the three months ended June 30, 2022 primarily resulted from a net loss of $8.6 million and change in fair value of long-term investment of $1.4 million and is partially offset by change in fair value of short-term investment of $1.6 million and unrealized loss on marketable securities of $2.3 million.

Cash Flows from Investing Activities

For the six months ended June 30, 2023 and 2022, net cash used in investing activities was approximately $14.7 million and $15.3 million, respectively. The cash used in investing activities for the six months ended June 30, 2023, primarily resulted from our purchase of marketable securities of approximately $34.0 million and the acquisition of FPS of approximately $1.1 million, partially offset by our sale of marketable securities of approximately $20.5 million. The Company also collected approximately $0.5 million in principal related to its short-term notes. The cash used in investing activities for the six months ended June 30, 2022 primarily resulted from our purchase of marketable securities of $27.5 million, purchase of promissory notes of $1.6 million and purchase of investments of $14.6 million, partially offset by our sale of marketable securities of $28.3 million since we invest excess cash into marketable securities until additional cash is needed.

Cash Flows from Financing Activities

For the six months ended June 30, 2023, cash used in financing activities was approximately $0.9 million, which reflects the cost for purchase of treasury stock of approximately $0.9 million. Cash used in financing activities for the six months ended June 30, 2022 was $5.6 million, which reflects the cost for redemption of Series O and Series P Redeemable Convertible Preferred Stock of $22.0 million and cost for purchase of treasury stock of $1.5 million, partially offset by net proceeds of $17.9 million from investors in exchange of issuance of issuance of Series O and Series P Redeemable Convertible Preferred Stock.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for smaller reporting companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed or submitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act are accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

During the quarter ended June 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective, as of the end of the period covered by this report.

Changes in Internal Control Over Financial Reporting

We have not made any changes to our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls

Our management does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

Part II. Other Information

Item 1. Legal Proceedings

In the past, in the ordinary course of business, we actively pursued legal remedies to enforce our intellectual property rights and to stop unauthorized use of our technology. Other than ordinary routine litigation incidental to the business, we know of no material, active or pending legal proceedings against us.

Item 1A. Risk Factors

Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information contained in this Quarterly Report on Form 10-Q and in the other periodic and current reports and other documents we file with the Securities and Exchange Commission, including but not limited to our annual report on Form 10-K for the fiscal year ended December 31, 2022, before deciding to invest in our common stock. If any of the following risks materialize, our business, financial condition, results of operation and future prospects will likely be materially and adversely affected. In that event, the market price of our common stock could decline and you could lose all or part of your investment. This list is not exhaustive and the order of presentation does not reflect management’s determination of priority or likelihood.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

None.

Item 6. Exhibits

10.1		Employment Agreement, made and entered into as of April 3, 20234, by and between Dominari Securities LLC and Soo Yu filed with the Securities and Exchange Commission on May 11, 2023, as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023
10.2		Amendment to Employment Agreement, made and entered into as of April 19, 2023, by and between Dominari Securities LLC and Soo Yu filed with the Securities and Exchange Commission on May 11, 2023, as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023
31.1*		Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*		Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Filed herewith

Signatures

Pursuant to the requirements of the Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DOMINARI HOLDINGS INC.

Date: August 9, 2023	By:	/s/ Anthony Hayes
		Anthony Hayes
		Chief Executive Officer
		(Principal Executive Officer)


Date: August 9, 2023	By:	/s/ George Way
		George Way
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

1.18 1.79 2.42 2.45 4827239 5065055 5251023 5251766 false --12-31 Q2 0000012239 0000012239 2023-01-01 2023-06-30 0000012239 2023-08-08 0000012239 2023-06-30 0000012239 2022-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2023-06-30 0000012239 us-gaap:SeriesDPreferredStockMember 2022-12-31 0000012239 domh:SeriesD1PreferredStockMember 2023-06-30 0000012239 domh:SeriesD1PreferredStockMember 2022-12-31 0000012239 2023-04-01 2023-06-30 0000012239 2022-04-01 2022-06-30 0000012239 2022-01-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2023-03-31 0000012239 us-gaap:CommonStockMember 2023-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-03-31 0000012239 us-gaap:RetainedEarningsMember 2023-03-31 0000012239 2023-03-31 0000012239 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000012239 us-gaap:PreferredStockMember 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-03-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-03-31 0000012239 us-gaap:CommonStockMember 2022-03-31 0000012239 us-gaap:PreferredStockMember 2022-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-03-31 0000012239 us-gaap:RetainedEarningsMember 2022-03-31 0000012239 2022-03-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-06-30 0000012239 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-12-31 0000012239 us-gaap:CommonStockMember 2022-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012239 us-gaap:RetainedEarningsMember 2022-12-31 0000012239 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:CommonStockMember 2021-12-31 0000012239 us-gaap:PreferredStockMember 2021-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2021-12-31 0000012239 us-gaap:RetainedEarningsMember 2021-12-31 0000012239 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-01-01 2022-06-30 0000012239 domh:FPSPurchaseAgreementMember 2022-09-09 0000012239 domh:FPSPurchaseAgreementMember 2022-10-01 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2023-01-01 2023-06-30 0000012239 domh:FPSPurchaseAgreementMember 2023-06-30 0000012239 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-03-27 0000012239 domh:InvestmentInVicinityMotorCorpMember 2023-01-01 2023-06-30 0000012239 domh:InvestmentInVicinityMotorCorpMember 2022-01-01 2022-12-31 0000012239 domh:InvestmentInVicinityMotorCorpMember 2023-06-30 0000012239 domh:InvestmentInVicinityMotorCorpMember 2022-12-31 0000012239 domh:VicinityMotorCorpMember 2023-01-01 2023-06-30 0000012239 domh:VicinityMotorCorpMember 2022-01-01 2022-12-31 0000012239 2021-11-22 2021-11-22 0000012239 2023-03-01 2023-03-31 0000012239 2023-06-01 2023-06-30 0000012239 domh:InvestmentInKernaHealthIncMember 2023-06-30 0000012239 domh:InvestmentInKernaHealthIncMember 2022-12-31 0000012239 domh:InvestmentInKayaNowMember 2023-06-30 0000012239 domh:InvestmentInKayaNowMember 2022-12-31 0000012239 domh:InvestmentInTevvaMotorsMember 2023-06-30 0000012239 domh:InvestmentInTevvaMotorsMember 2022-12-31 0000012239 domh:InvestmentInASPIsotopesMember 2023-06-30 0000012239 domh:InvestmentInASPIsotopesMember 2022-12-31 0000012239 domh:InvestmentInAerocarveUSCorporationMember 2023-06-30 0000012239 domh:InvestmentInAerocarveUSCorporationMember 2022-12-31 0000012239 domh:InvestmentInQxpressMember 2023-06-30 0000012239 domh:InvestmentInQxpressMember 2022-12-31 0000012239 domh:InvestmentInMasterclassMember 2023-06-30 0000012239 domh:InvestmentInMasterclassMember 2022-12-31 0000012239 domh:InvestmentInKrakenMember 2023-06-30 0000012239 domh:InvestmentInKrakenMember 2022-12-31 0000012239 domh:InvestmentInEpicGamesMember 2023-06-30 0000012239 domh:InvestmentInEpicGamesMember 2022-12-31 0000012239 domh:InvestmentInTesspayMember 2023-06-30 0000012239 domh:InvestmentInTesspayMember 2022-12-31 0000012239 domh:InvestmentInSpaceXMember 2023-06-30 0000012239 domh:InvestmentInSpaceXMember 2022-12-31 0000012239 domh:InvestmentInDatabricksMember 2023-06-30 0000012239 domh:InvestmentInDatabricksMember 2022-12-31 0000012239 domh:InvestmentInDiscordMember 2023-06-30 0000012239 domh:InvestmentInDiscordMember 2022-12-31 0000012239 domh:InvestmentInThrasioMember 2023-06-30 0000012239 domh:InvestmentInThrasioMember 2022-12-31 0000012239 domh:InvestmentInAutomationAnywhereMember 2023-06-30 0000012239 domh:InvestmentInAutomationAnywhereMember 2022-12-31 0000012239 domh:InvestmentInAndurilMember 2023-06-30 0000012239 domh:InvestmentInAndurilMember 2022-12-31 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-06-30 0000012239 us-gaap:NotesPayableOtherPayablesMember domh:ConvergentTherapeuticsIncInvestmentMember 2023-06-30 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-06-30 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:KayaNowPromissoryNoteMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteCurrentPortionMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteCurrentPortionMember 2023-06-30 0000012239 domh:ConvergentConvertibleNoteNoncurrentPortionMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteNoncurrentPortionMember 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-06-30 0000012239 domh:NotesReceivableAtFairvalueCurrentPortionMember 2023-06-30 0000012239 domh:NotesReceivableAtFairvalueNoncurrentPortionMember 2023-06-30 0000012239 us-gaap:FairValueInputsLevel1Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel2Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel3Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0000012239 2023-01-11 0000012239 2022-09-23 0000012239 2022-09-23 2022-09-23 0000012239 domh:OperatingLeaseMember 2023-06-30 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-06-30 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-06-30 0000012239 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000012239 us-gaap:WarrantMember 2022-01-01 2022-06-30 0000012239 us-gaap:EmployeeStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:EmployeeStockMember 2022-01-01 2022-06-30 0000012239 2023-03-06 0000012239 2023-03-20 0000012239 us-gaap:CommonStockMember 2023-06-01 2023-06-27 0000012239 2023-06-01 2023-06-27 0000012239 2022-01-01 2022-01-21 0000012239 2023-03-01 2023-03-06 0000012239 us-gaap:OverAllotmentOptionMember 2023-01-01 2023-06-30 0000012239 us-gaap:OverAllotmentOptionMember 2022-01-01 2022-06-30 0000012239 us-gaap:WarrantMember 2021-12-31 0000012239 us-gaap:WarrantMember 2022-12-31 0000012239 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000012239 us-gaap:WarrantMember 2023-06-30 0000012239 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-04-01 2023-06-30 0000012239 domh:LegacyAIkidoPharmaMember 2023-04-01 2023-06-30 0000012239 domh:ConsolidatedMember 2023-04-01 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-01-01 2023-06-30 0000012239 domh:ConsolidatedMember 2023-01-01 2023-06-30 0000012239 domh:LegacyAIkidoPharmaMember 2023-01-01 2023-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Anthony Hayes, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2023

	/s/ Anthony Hayes
	Anthony Hayes
	Chief Executive Officer
	(Principal Executive Officer)

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, George Way, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2023
	/s/ George Way
	George Way
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Anthony Haynes, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.


Date: August 9, 2023

	/s/ Anthony Haynes
	Anthony Haynes
	Chief Executive Officer
	(Principal Executive Officer)

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, George Way, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.


Date: August 9, 2023

	/s/ George Way
	George Way
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2023	Aug. 08, 2023
Document Information Line Items
Entity Registrant Name	DOMINARI HOLDINGS INC.
Trading Symbol	DOMH
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		5,345,312
Amendment Flag	false
Entity Central Index Key	0000012239
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-05576
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	52-0849320
Entity Address, Address Line One	725 5th Avenue
Entity Address, Address Line Two	22nd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
City Area Code	(703)
Local Phone Number	992-9325
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 3,598	$ 33,174
Marketable securities	20,675	7,130
Deposits with clearing broker	7,082
Prepaid expenses and other assets	715	564
Prepaid acquisition cost		301
Short-term investments, at fair value	13	13
Notes receivable, at fair value - current portion	6,339	7,474
Investment in Fieldpoint Securities		2,000
Total current assets	38,422	50,656
Property and equipment, net	387
Notes receivable, at fair value - non-current portion	1,622	1,100
Employee forgivable loan receivable	98
Investments	23,178	23,103
Right-of-use assets	3,530	919
Security deposit	458	458
Total assets	67,695	76,236
Current liabilities
Accounts payable and accrued expenses	232	447
Accrued salaries and benefits	632	1,260
Income taxes withheld	1,300
Accrued Commissions	17
Lease liability - current	353	82
Other Current liability	124
Total current liabilities	2,658	1,789
Lease liability	3,259	680
Total liabilities	5,917	2,469
Stockholders’ equity
Preferred stock value
Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,345,312 and 5,485,096 shares issued at June 30, 2023 and December 31, 2022, respectively; 5,285,164 and 5,017,079 shares outstanding at June 30, 2023 and December 31, 2022, respectively
Additional paid-in capital	260,585	262,970
Treasury stock, at cost, 60,148 and 468,017 shares at June 30, 2023 and December 31, 2022, respectively	(501)	(3,322)
Accumulated deficit	(198,306)	(185,881)
Total stockholders’ equity	61,778	73,767
Total liabilities and stockholders’ equity	67,695	76,236
Series D Preferred Stock
Stockholders’ equity
Preferred stock value
Series D-1 Preferred Stock
Stockholders’ equity
Preferred stock value

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	50,000,000	50,000,000
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	5,345,312	5,485,096
Common stock, shares outstanding	5,285,164	5,017,079
Treasury stock, at cost	60,148	468,017
Series D Preferred Stock
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	3,825	3,825
Preferred stock, outstanding	3,825	3,825
Liquidation preference (in Dollars per share)	$ 0.0001	$ 0.0001
Series D-1 Preferred Stock
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	834	834
Preferred stock, outstanding	834	834
Liquidation preference (in Dollars per share)	$ 0.0001	$ 0.0001

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues	$ 71		$ 71
Operating costs and expenses
General and administrative	9,080	2,262	12,913	4,049
Research and development	2	36	3	2,052
Total operating expenses	9,082	2,298	12,916	6,101
Loss from operations	(9,011)	(2,298)	(12,845)	(6,101)
Other income (expenses)
Other income				64
Interest income	160	220	297	399
Gain (loss) on marketable securities	400	(2,239)	335	(2,736)
Unrealized loss on note receivable	(212)		(212)
Change in fair value of investments		(760)		(238)
Total other income (expenses)	348	(2,779)	420	(2,511)
Net loss	(8,663)	(5,077)	(12,425)	(8,612)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock		(1,100)		(4,109)
Net Loss Attributable to Common Shareholders	$ (8,663)	$ (6,177)	$ (12,425)	$ (12,721)
Net loss per share, basic and diluted
Basic (in Dollars per share)	$ (1.79)	$ (1.18)	$ (2.45)	$ (2.42)
Weighted average number of shares outstanding, basic and diluted
Basic (in Shares)	4,827,239	5,251,023	5,065,055	5,251,766

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Diluted	$ (1.79)	$ (1.18)	$ (2.45)	$ (2.42)
Diluted	4,827,239	5,251,023	5,065,055	5,251,766

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity - USD ($) $ in Thousands	Redeemable Convertible Preferred Stock Series O	Redeemable Convertible Preferred Stock Series P	Preferred Stock	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Total
Balance at Dec. 31, 2021					$ 265,633	$ (264)	$ (163,774)	$ 101,595
Balance (in Shares) at Dec. 31, 2021			4,659	5,275,329
Redemption of Series O Redeemable Convertible Preferred Stock	$ (11,000)
Redemption of Series O Redeemable Convertible Preferred Stock (in Shares)	(11,000)
Redemption of Series P Redeemable Convertible Preferred Stock		$ (11,000)
Redemption of Series P Redeemable Convertible Preferred Stock (in Shares)		(11,000)
Issuance of Series O redeemable convertible preferred stock for cash	$ 11,000
Issuance of Series O redeemable convertible preferred stock for cash (in Shares)	11,000
Issuance of Series P redeemable convertible preferred stock for cash		$ 11,000
Issuance of Series P redeemable convertible preferred stock for cash (in Shares)		11,000
Cost on issuance of Series O and Series P Redeemable Convertible Preferred Stock	(1,504)	$ (1,505)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock	1,504	1,505			(4,109)			(4,109)
Repurchase of treasury stock						$ (1,486)		(1,486)
Repurchase of treasury stock (in Shares)						242,902
Stock-based compensation					105			105
Cancellation of common stock related to investment in CBM
Cancellation of common stock related to investment in CBM (in Shares)				(22,812)
Fractional shares adjusted for reverse split					(26)			(26)
Fractional shares adjusted for reverse split (in Shares)				(5,665)
Net loss							(8,612)	(8,612)
Balance at Jun. 30, 2022					261,603	$ (1,750)	(172,386)	87,467
Balance (in Shares) at Jun. 30, 2022			4,659	5,246,852		242,902
Balance at Mar. 31, 2022	$ 11,000	$ 11,000			262,624	$ (264)	(167,309)	95,051
Balance (in Shares) at Mar. 31, 2022	11,000	11,000	4,659	5,252,517
Redemption of Series O Redeemable Convertible Preferred Stock	$ (11,000)
Redemption of Series O Redeemable Convertible Preferred Stock (in Shares)	(11,000)
Redemption of Series P Redeemable Convertible Preferred Stock		$ (11,000)
Redemption of Series P Redeemable Convertible Preferred Stock (in Shares)		(11,000)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock					(1,100)			(1,100)
Repurchase of treasury stock						$ (1,486)		(1,486)
Repurchase of treasury stock (in Shares)						242,902
Stock-based compensation					105			105
Fractional shares adjusted for reverse split					(26)			(26)
Fractional shares adjusted for reverse split (in Shares)				(5,665)
Net loss							(5,077)	(5,077)
Balance at Jun. 30, 2022					261,603	$ (1,750)	(172,386)	87,467
Balance (in Shares) at Jun. 30, 2022			4,659	5,246,852		242,902
Balance at Dec. 31, 2022					262,970	$ (3,322)	(185,881)	73,767
Balance (in Shares) at Dec. 31, 2022			4,659	5,485,096		468,017
Stock-based compensation					1,375			1,375
Stock-based compensation (in Shares)				529,715
Cancellation of common stock
Cancellation of common stock (in Shares)				(25,000)
Purchase of treasury stock (in Shares)						(939,000)		(939,000)
Purchase of treasury stock (in Shares)						236,630
Retirement of treasury stock					$ (3,760)	$ 3,760
Retirement of treasury stock (in Shares)				(644,499)		(644,499)
Net loss							(12,425)	(12,425)
Balance at Jun. 30, 2023					260,585	$ (501)	(198,306)	61,778
Balance (in Shares) at Jun. 30, 2023			4,659	5,345,312		60,148
Balance at Mar. 31, 2023					259,215	$ (501)	(189,643)	69,071
Balance (in Shares) at Mar. 31, 2023			4,659	4,815,597		60,148
Stock-based compensation					1,370			1,370
Stock-based compensation (in Shares)				529,715
Net loss							(8,663)	(8,663)
Balance at Jun. 30, 2023					$ 260,585	$ (501)	$ (198,306)	$ 61,778
Balance (in Shares) at Jun. 30, 2023			4,659	5,345,312		60,148

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss	$ (12,425)	$ (8,612)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of right-of-use assets	182
Depreciation	32
Change in fair value of short-term investment		1,646
Change in fair value of long-term investment		(1,408)
Stock-based compensation	2,675	105
Realized loss on marketable securities	487	568
Unrealized (gain) loss on marketable securities	(514)	2,299
Unrealized loss on note receivable	212
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(229)	153
Prepaid acquisition cost	301
Deposits with clearing broker	(3,532)
Accounts payable and accrued expenses	(428)	(239)
Accrued salaries and benefits	(628)	7
Accrued commissions	(8)
Lease liabilities	58
Other current liabilities	3
Notes receivable, at fair value – net interest accrued	(99)	(377)
Deposit		8
Net cash used in operating activities	(13,913)	(5,850)
Cash flows from investing activities
Purchase of marketable securities	(34,014)	(27,460)
Sale of marketable securities	20,494	28,272
Proceeds from sale of digital currencies		93
Purchase of fixed assets	(419)
Acquisition of FPS, net of cash acquired and receivable owed from FPS	(1,112)
Collection of principal on note receivable	502
Funds to employee forgivable loan	(100)
Purchase of short-term and long-term investments	(75)	(14,605)
Purchase of short-term and long-term promissory notes		(1,600)
Net cash used in investing activities	(14,724)	(15,300)
Cash flows from financing activities
Proceeds from issuance of Series O and Series P Redeemable Convertible Preferred Stock, net of discount and offering cost		17,891
Payment for fractional shares		(26)
Redemption of Series O and Series P Redeemable Convertible Preferred Stock		(22,000)
Purchase of treasury stock	(939)	(1,486)
Net cash used in financing activities	(939)	(5,621)
Net decrease in cash and cash equivalents and restricted cash	(29,576)	(26,771)
Cash and cash equivalents, beginning of period	33,174	65,562
Cash and cash equivalents, end of period	3,598	38,791
Non-cash investing and financing activities
Transfer from short-term investment to marketable securities		1,482
Reclassify from convertible note receivable to notes receivable at fair value		2,147
Promissory convertible note receivable conversion into common shares		$ 1,508
On March 27, 2023, the Company acquired all assets and liabilities of FPS as disclosed in Note 4:
Net assets acquired, net of cash acquired and receivable owed from FPS	3,112
Less - Deposit previously transferred in October 2022 to FPS	(2,000)
Net cash paid	$ 1,112

Organization and Description of Business and Recent Developments

6 Months Ended

Jun. 30, 2023

Organization and Description of Business and Recent Developments [Abstract]

Organization and Description of Business and Recent Developments

Note 1. Organization and Description of Business and Recent Developments

Organization and Description of Business

Liquidity and Capital Resources

6 Months Ended

Jun. 30, 2023

Liquidity and Capital Resources [Abstract]

Liquidity and Capital Resources

Note 2. Liquidity and Capital Resources

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3. Summary of Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2022 Annual Report other than those discussed below.

Basis of Presentation and Principles of Consolidation

Results for interim periods are not necessarily indicative of results to be expected for a full year or any future period.

Use of Estimates

Deposits with clearing broker

Leases

Revenue

The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:

●

Recently adopted accounting standards

Effect of new accounting pronouncements not yet adopted

Effect of new accounting pronouncements to be adopted in future periods

FPS Acquisition

6 Months Ended

Jun. 30, 2023

FPS Acquisition [Abstract]

FPS Acquisition

Note 4. FPS Acquisition

Consideration Transferred

The FPS Acquisition was accounted for as a business combination under ASC 805.

Fair Value of Net Assets Acquired

The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition:

	March 27,
	2023
	(Unaudited)
ASSETS
Cash and cash equivalents	$	92
Deposits with Clearing Broker-Dealer		3,550
Other receivables		53
Prepaid and other current assets		89
Total assets acquired		3,784

Liabilities
Accrued expenses	$	273
Accrued commissions		25
Wealth management liabilities		62
Total liabilities assumed		360

Total net assets of FPS Acquisition		3,424

Investments in Marketable Securities

6 Months Ended

Jun. 30, 2023

Investments, Debt and Equity Securities [Abstract]

Investments in Marketable Securities

Note 5. Investments in Marketable Securities

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Realized loss	$	(432	)	$	(344	)	$	(487	)	$	(568	)
Unrealized gain (loss)		643			(1,967	)		514			(2,299	)
Dividend income		188			72			308			131
Total	$	400		$	(2,239	)	$	335		$	(2,736	)

Short-Term Investments

6 Months Ended

Jun. 30, 2023

Short-Term Investments [Abstract]

Short-term investments

Note 6. Short-term investments

The following table presents the Company’s short-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):

	June 30, 2023		December 31, 2022
Investment in Vicinity Motor Corp.		13		13
Total		13		13

There was no change in the fair value of the short-term investments for the six months ended June 30, 2023.

The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:

	June 30, 2023			December 31, 2022
Option term (in years)		1.3			1.8
Volatility		76.9	%		76.90	%
Risk-free interest rate		4.47	%		4.47	%
Expected dividends		0.00	%		0.00	%
Stock price	$	0.96		$	0.96

Long-Term Investments

6 Months Ended

Jun. 30, 2023

Long-Term Investments [Abstract]

Long-Term Investments

Note 7. Long-Term Investments

	Cost Basis		June 30, 2023		December 31, 2022
Investment in Kerna Health Inc	$	2,140	$	4,940	$	4,940
Investment in Kaya Now		1,500		-		-
Investment in Tevva Motors		1,972		2,794		2,794
Investment in ASP Isotopes		1,300		-		-
Investment in AerocarveUS Corporation		1,075		1,075		1,000
Investment in Qxpress		1,000		1,000		1,000
Investment in Masterclass		170		170		170
Investment in Kraken		597		597		597
Investment in Epic Games		3,500		3,500		3,500
Investment in Tesspay		1,240		2,500		2,500
Investment in SpaceX		3,500		3,674		3,674
Investment in Databricks		1,200		1,200		1,200
Investment in Discord		476		476		476
Investment in Thrasio		300		300		300
Investment in Automation Anywhere		476		476		476
Investment in Anduril		476		476		476
Total	$	20,922	$	23,178	$	23,103

Investment in AerocarveUS Corporation

Notes Receivable

6 Months Ended

Jun. 30, 2023

Notes Receivable [Abstract]

Notes Receivable

Note 8. Notes Receivable

The following table presents the Company’s notes receivable as of June 30, 2023 ($ in thousands):

	Maturity Date	Stated Interest Rate			Principal Amount		Interest Receivable		Fair Value
Notes receivable, at fair value
Convergent convertible note - current	01/29/2023		8	%	$	1,000	$	199	$	1,199
Convergent convertible note - non-current	01/29/2023		8	%	$	500	$	-	$	500
Raefan Industries LLC Investment	12/31/2023		8	%	$	4,518	$	623	$	5,141
American Innovative Robotics Investment	04/01/2027		8	%	$	1,100	$	22	$	1,122

Notes receivable, at fair value - current portion									$	6,339

Notes receivable, at fair value - non-current portion									$	1,622

Convergent Therapeutics, Inc. Investment

Raefan Industries LLC Investment

American Innovative Robotics, LLC Investment

The Company recorded interest income of approximately $44,000 on the Robotics Promissory Note for the six months ended June 30, 2023.

Kaya Now Inc. Investment

The Company received and recorded interest income related to the Kaya Now Promissory Note of approximately $10,000 for the six months ended June 30, 2023.

Fair Value of Financial Assets and Liabilities

6 Months Ended

Jun. 30, 2023

Fair Value of Financial Assets and Liabilities [Abstract]

Fair Value of Financial Assets and Liabilities

Note 9. Fair Value of Financial Assets and Liabilities

The Company uses three levels of inputs that may be used to measure fair value:

Level 1 - quoted prices in active markets for identical assets or liabilities

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2023, and December 31, 2022 ($ in thousands):

	Fair value measured as of June 30, 2023
	Total at June 30,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2023		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities:
Equities	$	20,675	$	20,675	$	-	$	-
Total marketable securities	$	20,675	$	20,675	$	-	$	-
Short-term investment	$	13	$	-	$	-	$	13
Notes receivable at fair value, current portion	$	6,339	$	-	$	-	$	6,339
Notes receivable at fair value, non-current portion	$	1,622	$	-	$	-	$	1,622

	Fair value measured as of December 31, 2022
	Total at December 31,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities:
Equities	$	7,130	$	7,130	$	-	$	-
Total marketable securities	$	7,130	$	7,130	$	-	$	-
Short-term investment	$	13	$	-	$	-	$	13
Notes receivable at fair value, current portion	$	7,474	$	-	$	-	$	7,474
Notes receivable at fair value, non-current portion	$	1,100	$	-	$	-	$	1,100

Level 3 Measurement

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

Short-term investment at December 31, 2022	$	13
Short-term investment at June 30, 2023	$	13

Notes receivable at fair value, current portion at December 31, 2022	$	7,474
Collection of principal outstanding		(500	)
Note receivable, Convergent Therapeutics, non-current portion		(500	)
Unrealized loss on note receivable		(212	)
Accrued interest receivable		77
Notes receivable at fair value, current portion at June 30, 2023	$	6,339

Notes receivable at fair value, non-current portion at December 31, 2022	$	1,100
Note receivable, Convergent Therapeutics, non-current portion		500
Accrued interest receivable		22
Notes receivable at fair value, non-current portion at June 30, 2023	$	1,622

Note Receivable at fair value

Leases

6 Months Ended

Jun. 30, 2023

Leases [Abstract]

Leases

Note 10. Leases

The tables below represent the Company’s lease assets and liabilities as of June 30, 2023:

	June 30, 2023
Assets:
Operating lease right-of-use-assets	$	3,530

Liabilities:
Current
Operating		353
Long-term
Operating		3,259
	$	3,612

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

June 30,

2023

Weighted-average remaining lease term – operating leases (in years)

7.0

Weighted-average discount rate – operating leases

10.0

During the six months ended June 30, 2023, the Company recorded approximately $0.4 million of lease expense to current period operations.

	Three Months Ended		Six Months Ended
	June 30, 2023		June 30, 2023
Operating leases
Operating lease cost	$	179	$	313
Operating lease expense		179		313
Short-term lease rent expense		33		63
Net rent expense	$	212	$	376

Supplemental cash flow information related to leases were as follows:

	Six Months Ended
	June 30, 2023
Operating cash flows - operating leases	$	72
Right-of-use assets obtained in exchange for operating lease liabilities	$	2,796

As of June 30, 2023, future minimum payments during the next five years and thereafter are as follows:

	Operating
	Leases
Remaining Period Ended December 31, 2023	$	327
Year Ended December 31, 2024		750
Year Ended December 31, 2025		688
Year Ended December 31, 2026		688
Year Ended December 31, 2027		688
Year Ended December 31, 2028		770
Thereafter		1,166
Total		5,077
Less present value discount		(1,465	)
Operating lease liabilities	$	3,612

Net Loss per Share

6 Months Ended

Jun. 30, 2023

Net Loss per Share [Abstract]

Net Loss per Share

Note 11. Net Loss per Share

	As of June 30,
	2023		2022
Convertible preferred stock		34		34
Warrants to purchase common stock		444,796		444,796
Options to purchase common stock		30,336		198,574
Total		475,166		643,404

Stockholders’ Equity and Convertible Preferred Stock

6 Months Ended

Jun. 30, 2023

Stockholders’ Equity and Convertible Preferred Stock [Abstract]

Stockholders’ Equity and Convertible Preferred Stock

Note 12. Stockholders’ Equity and Convertible Preferred Stock

Common Stock

On March 6, 2023, the Company cancelled 644,499 shares of common stock as a result of retirement of 644,499 shares of treasury stock.

On March 20, 2023, the Company cancelled 25,000 shares of common stock owned by a board member.

Treasury Stock

On March 6, 2023, the Company retired 644,499 shares of treasury stock with original cost of approximately $3.8 million.

Warrants

A summary of warrant activity for the six months ended June 30, 2023, is presented below:

	Warrants		Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2022		444,796	$	29.25		-		3.20
Outstanding as of June 30, 2023		444,796	$	29.25		-		2.71

Restricted Stock Awards

A summary of restricted stock awards activity for the six months ended June 30, 2023, is presented below:

	Number of Restricted Stock Awards			Weighted Average Grant Day Fair Value
Nonvested at December 31, 2022		8,068		$	5.64
Granted		529,715		$	2.58
Vested		(537,783	)		2.63
Nonvested at June 30, 2023		-		$	-

As of June 30, 2023, there is no unrecognized stock-based compensation expense related to restricted stock awards.

Stock Options

A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2023 is presented below:

	Number of Shares			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2022		31,193		$	302.97	$	-		7.9
Employee options expired		(857	)	$	9,719.07
Outstanding as of June 30, 2023		30,336		$	36.97	$	-		7.6
Options vested and exercisable		26,578		$	41.35	$	-		7.5

Estimated future stock-based compensation expense relating to unvested stock options is approximately $7,000.

Revenue

6 Months Ended

Jun. 30, 2023

Revenue [Abstract]

Revenue

Note 13. Revenue

The following table presents our total revenues disaggregated by revenue type for the three and six months ended June 30, 2023 and 2022 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2023			2022		2023		2022
Underwriting	$	43	$	-	$	43	$	-
Commissions		14		-		14		-
Other		14		-	$	14		-
Total	$	71	$	-	$	71	$	-

Commitments and Contingencies

6 Months Ended

Jun. 30, 2023

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Note 14. Commitments and Contingencies

Legal Proceedings

Regulatory

6 Months Ended

Jun. 30, 2023

Regulatory [Abstract]

Regulatory

Note 15. Regulatory

Related Party Transaction

6 Months Ended

Jun. 30, 2023

Related Party Transaction

Note 16. Related Party Transaction

Segment Reporting

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Segment Reporting

Note 17. Segment Reporting

The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.

	Three Months Ended June 30, 2023
	Dominari Securities			Legacy AIkido Pharma			Consolidated
Revenue	$	71		$	-		$	71
Operating Costs
General and administrative		6,957			2,123		$	9,080
Research and development					2			2
Loss from operations	$	(6,886	)	$	(2,125	)	$	(9,011	)

Other (expenses) income
Other income								-
Interest income		44			116			160
Loss on marketable securities					400			400
Unrealized loss on note receivable					(212	)		(212	)
Total other (expenses) income	$	44		$	304		$	348
Net loss	$	(6,842	)	$	(1,821	)	$	(8,663	)

	Six Months Ended June 30, 2023
	Dominari Securities			Legacy AIkido Pharma			Consolidated
Revenue	$	71		$	-		$	71
Operating Costs
General and administrative		8,056			4,857			12,913
Research and development					3			3
Loss from operations	$	(7,985	)	$	(4,860	)	$	(12,845	)

Other (expenses) income
Other income					-			-
Interest income		44			253			297
Loss on marketable securities					335			335
Unrealized loss on note receivable					(212	)		(212	)
Total other (expenses) income	$	44		$	376		$	420
Net loss	$	(7,941	)	$	(4,484	)	$	(12,425	)

Accounting Policies, by Policy (Policies)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

Results for interim periods are not necessarily indicative of results to be expected for a full year or any future period.

Use of Estimates

Use of Estimates

Deposits with clearing broker

Deposits with clearing broker

Leases

Leases

Revenue

Revenue

The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:

●

Recently adopted accounting standards

Recently adopted accounting standards

Effect of new accounting pronouncements not yet adopted

Effect of new accounting pronouncements not yet adopted

Effect of new accounting pronouncements to be adopted in future periods

Effect of new accounting pronouncements to be adopted in future periods

FPS Acquisition (Tables)

6 Months Ended

Jun. 30, 2023

FPS Acquisition [Abstract]

Schedule of Fair Values of the Assets Acquired And Liabilities

The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition:

	March 27,
	2023
	(Unaudited)
ASSETS
Cash and cash equivalents	$	92
Deposits with Clearing Broker-Dealer		3,550
Other receivables		53
Prepaid and other current assets		89
Total assets acquired		3,784

Liabilities
Accrued expenses	$	273
Accrued commissions		25
Wealth management liabilities		62
Total liabilities assumed		360

Total net assets of FPS Acquisition		3,424

Investments in Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2023

Investments, Debt and Equity Securities [Abstract]

Schedule of Marketable Securities

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Realized loss	$	(432	)	$	(344	)	$	(487	)	$	(568	)
Unrealized gain (loss)		643			(1,967	)		514			(2,299	)
Dividend income		188			72			308			131
Total	$	400		$	(2,239	)	$	335		$	(2,736	)

Short-Term Investments (Tables)

6 Months Ended

Jun. 30, 2023

Short-Term Investments [Abstract]

Schedule of Short-Term Investments

The following table presents the Company’s short-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):

	June 30, 2023		December 31, 2022
Investment in Vicinity Motor Corp.		13		13
Total		13		13

Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs

The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:

	June 30, 2023			December 31, 2022
Option term (in years)		1.3			1.8
Volatility		76.9	%		76.90	%
Risk-free interest rate		4.47	%		4.47	%
Expected dividends		0.00	%		0.00	%
Stock price	$	0.96		$	0.96

Long-Term Investments (Tables)

6 Months Ended

Jun. 30, 2023

Long-Term Investments [Abstract]

Schedule of Long-Term Investments

The following table presents the Company’s long-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):

	Cost Basis		June 30, 2023		December 31, 2022
Investment in Kerna Health Inc	$	2,140	$	4,940	$	4,940
Investment in Kaya Now		1,500		-		-
Investment in Tevva Motors		1,972		2,794		2,794
Investment in ASP Isotopes		1,300		-		-
Investment in AerocarveUS Corporation		1,075		1,075		1,000
Investment in Qxpress		1,000		1,000		1,000
Investment in Masterclass		170		170		170
Investment in Kraken		597		597		597
Investment in Epic Games		3,500		3,500		3,500
Investment in Tesspay		1,240		2,500		2,500
Investment in SpaceX		3,500		3,674		3,674
Investment in Databricks		1,200		1,200		1,200
Investment in Discord		476		476		476
Investment in Thrasio		300		300		300
Investment in Automation Anywhere		476		476		476
Investment in Anduril		476		476		476
Total	$	20,922	$	23,178	$	23,103

Notes Receivable (Tables)

6 Months Ended

Jun. 30, 2023

Notes Receivable [Abstract]

Schedule of Notes Receivable

The following table presents the Company’s notes receivable as of June 30, 2023 ($ in thousands):

	Maturity Date	Stated Interest Rate			Principal Amount		Interest Receivable		Fair Value
Notes receivable, at fair value
Convergent convertible note - current	01/29/2023		8	%	$	1,000	$	199	$	1,199
Convergent convertible note - non-current	01/29/2023		8	%	$	500	$	-	$	500
Raefan Industries LLC Investment	12/31/2023		8	%	$	4,518	$	623	$	5,141
American Innovative Robotics Investment	04/01/2027		8	%	$	1,100	$	22	$	1,122

Notes receivable, at fair value - current portion									$	6,339

Notes receivable, at fair value - non-current portion									$	1,622

Fair Value of Financial Assets and Liabilities (Tables)

6 Months Ended

Jun. 30, 2023

Fair Value of Financial Assets and Liabilities [Abstract]

Schedule of Fair Value Assets and Liabilities

The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2023, and December 31, 2022 ($ in thousands):

	Fair value measured as of June 30, 2023
	Total at June 30,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2023		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities:
Equities	$	20,675	$	20,675	$	-	$	-
Total marketable securities	$	20,675	$	20,675	$	-	$	-
Short-term investment	$	13	$	-	$	-	$	13
Notes receivable at fair value, current portion	$	6,339	$	-	$	-	$	6,339
Notes receivable at fair value, non-current portion	$	1,622	$	-	$	-	$	1,622

	Fair value measured as of December 31, 2022
	Total at December 31,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets
Marketable securities:
Equities	$	7,130	$	7,130	$	-	$	-
Total marketable securities	$	7,130	$	7,130	$	-	$	-
Short-term investment	$	13	$	-	$	-	$	13
Notes receivable at fair value, current portion	$	7,474	$	-	$	-	$	7,474
Notes receivable at fair value, non-current portion	$	1,100	$	-	$	-	$	1,100

Schedule of Fair Value on a Recurring Basis

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

Short-term investment at December 31, 2022	$	13
Short-term investment at June 30, 2023	$	13

Notes receivable at fair value, current portion at December 31, 2022	$	7,474
Collection of principal outstanding		(500	)
Note receivable, Convergent Therapeutics, non-current portion		(500	)
Unrealized loss on note receivable		(212	)
Accrued interest receivable		77
Notes receivable at fair value, current portion at June 30, 2023	$	6,339

Notes receivable at fair value, non-current portion at December 31, 2022	$	1,100
Note receivable, Convergent Therapeutics, non-current portion		500
Accrued interest receivable		22
Notes receivable at fair value, non-current portion at June 30, 2023	$	1,622

Leases (Tables)

6 Months Ended

Jun. 30, 2023

Leases [Abstract]

Schedule of Lease Assets and Liabilities

The tables below represent the Company’s lease assets and liabilities as of June 30, 2023:

	June 30, 2023
Assets:
Operating lease right-of-use-assets	$	3,530

Liabilities:
Current
Operating		353
Long-term
Operating		3,259
	$	3,612

Schedule of Summarize Quantitative Information about The Company’s Operating Leases

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

June 30,

2023

Weighted-average remaining lease term – operating leases (in years)

7.0

Weighted-average discount rate – operating leases

10.0

Schedule of Lease Expense to Current Period Operations

During the six months ended June 30, 2023, the Company recorded approximately $0.4 million of lease expense to current period operations.

	Three Months Ended		Six Months Ended
	June 30, 2023		June 30, 2023
Operating leases
Operating lease cost	$	179	$	313
Operating lease expense		179		313
Short-term lease rent expense		33		63
Net rent expense	$	212	$	376

Schedule of Supplemental Cash Flow Information Related To Leases

Supplemental cash flow information related to leases were as follows:

	Six Months Ended
	June 30, 2023
Operating cash flows - operating leases	$	72
Right-of-use assets obtained in exchange for operating lease liabilities	$	2,796

Schedule of Future Minimum Payments

As of June 30, 2023, future minimum payments during the next five years and thereafter are as follows:

	Operating
	Leases
Remaining Period Ended December 31, 2023	$	327
Year Ended December 31, 2024		750
Year Ended December 31, 2025		688
Year Ended December 31, 2026		688
Year Ended December 31, 2027		688
Year Ended December 31, 2028		770
Thereafter		1,166
Total		5,077
Less present value discount		(1,465	)
Operating lease liabilities	$	3,612

Net Loss per Share (Tables)

6 Months Ended

Jun. 30, 2023

Net Loss per Share [Abstract]

Schedule of Computation of Diluted Loss Per Share

Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2023, and 2022 are as follows:

	As of June 30,
	2023		2022
Convertible preferred stock		34		34
Warrants to purchase common stock		444,796		444,796
Options to purchase common stock		30,336		198,574
Total		475,166		643,404

Stockholders’ Equity and Convertible Preferred Stock (Tables)

6 Months Ended

Jun. 30, 2023

Stockholders’ Equity and Convertible Preferred Stock [Abstract]

Schedule of Warrant Activity

A summary of warrant activity for the six months ended June 30, 2023, is presented below:

	Warrants		Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2022		444,796	$	29.25		-		3.20
Outstanding as of June 30, 2023		444,796	$	29.25		-		2.71

Schedule of Restricted Stock Awards Activity

A summary of restricted stock awards activity for the six months ended June 30, 2023, is presented below:

	Number of Restricted Stock Awards			Weighted Average Grant Day Fair Value
Nonvested at December 31, 2022		8,068		$	5.64
Granted		529,715		$	2.58
Vested		(537,783	)		2.63
Nonvested at June 30, 2023		-		$	-

Schedule of Stock Option Activity

A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2023 is presented below:

	Number of Shares			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2022		31,193		$	302.97	$	-		7.9
Employee options expired		(857	)	$	9,719.07
Outstanding as of June 30, 2023		30,336		$	36.97	$	-		7.6
Options vested and exercisable		26,578		$	41.35	$	-		7.5

Revenue (Tables)

6 Months Ended

Jun. 30, 2023

Revenue [Abstract]

Schedule of Total Revenues Disaggregated By Revenue

The following table presents our total revenues disaggregated by revenue type for the three and six months ended June 30, 2023 and 2022 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2023			2022		2023		2022
Underwriting	$	43	$	-	$	43	$	-
Commissions		14		-		14		-
Other		14		-	$	14		-
Total	$	71	$	-	$	71	$	-

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss

The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.

	Three Months Ended June 30, 2023
	Dominari Securities			Legacy AIkido Pharma			Consolidated
Revenue	$	71		$	-		$	71
Operating Costs
General and administrative		6,957			2,123		$	9,080
Research and development					2			2
Loss from operations	$	(6,886	)	$	(2,125	)	$	(9,011	)

Other (expenses) income
Other income								-
Interest income		44			116			160
Loss on marketable securities					400			400
Unrealized loss on note receivable					(212	)		(212	)
Total other (expenses) income	$	44		$	304		$	348
Net loss	$	(6,842	)	$	(1,821	)	$	(8,663	)

	Six Months Ended June 30, 2023
	Dominari Securities			Legacy AIkido Pharma			Consolidated
Revenue	$	71		$	-		$	71
Operating Costs
General and administrative		8,056			4,857			12,913
Research and development					3			3
Loss from operations	$	(7,985	)	$	(4,860	)	$	(12,845	)

Other (expenses) income
Other income					-			-
Interest income		44			253			297
Loss on marketable securities					335			335
Unrealized loss on note receivable					(212	)		(212	)
Total other (expenses) income	$	44		$	376		$	420
Net loss	$	(7,941	)	$	(4,484	)	$	(12,425	)

Summary of Significant Accounting Policies (Details) $ in Millions	Jun. 30, 2023 USD ($)
Accounting Policies [Abstract]
Money market funds	$ 7.1

FPS Acquisition (Details) - USD ($)		6 Months Ended
FPS Acquisition (Details) - USD ($)	Oct. 04, 2022	Jun. 30, 2023	Sep. 09, 2022
FPS Acquisition (Details) [Line Items]
Cash		$ 3,400,000
Transaction costs		900,000
Net loss		7,700,000
Revenue		70,000.00
Professional service costs		$ 5,400,000
FPS Purchase Agreement [Member]
FPS Acquisition (Details) [Line Items]
Membership interests rate	20.00%	80.00%	100.00%
Consideration amount	$ 2,000,000
Additional consideration		$ 1,600,000
Percentage of acquired membership interest		100.00%
Cash		$ 3,600,000
Purchase price		1
Net assets		3,400,000
Receivable amount		200,000
Transaction costs		$ 300,000

FPS Acquisition (Details) - Schedule of Fair Values of the Assets Acquired And Liabilities - Business Combination [Member] $ in Thousands	Mar. 27, 2023 USD ($)
ASSETS
Cash and cash equivalents	$ 92
Deposits with Clearing Broker-Dealer	3,550
Other receivables	53
Prepaid and other current assets	89
Total assets acquired	3,784
Liabilities
Accrued expenses	273
Accrued commissions	25
Wealth management liabilities	62
Total liabilities assumed	360
Total net assets of FPS Acquisition	$ 3,424

Investments in Marketable Securities (Details) - Schedule of Marketable Securities - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule of marketable securities [Abstract]
Realized loss	$ (432)	$ (344)	$ (487)	$ (568)
Unrealized gain (loss)	643	(1,967)	514	(2,299)
Dividend income	188	72	308	131
Total	$ 400	$ (2,239)	$ 335	$ (2,736)

Short-Term Investments (Details) - Schedule of Short-Term Investments - Investment in Vicinity Motor Corp. [Member] - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Short-Term Investments (Details) - Schedule of Short-Term Investments [Line Items]
Investment in Vicinity Motor Corp.	$ 13	$ 13
Total	$ 13	$ 13

Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs - Vicinity Motor Corp [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Short-Term Investments (Details) - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Inputs [Line Items]
Option term (in years)	1 year 3 months 18 days	1 year 9 months 18 days
Volatility	76.90%	76.90%
Risk-free interest rate	4.47%	4.47%
Expected dividends	0.00%	0.00%
Stock price (in Dollars per share)	$ 0.96	$ 0.96

Long-Term Investments (Details) - USD ($) $ in Thousands		1 Months Ended
Long-Term Investments (Details) - USD ($) $ in Thousands	Nov. 22, 2021	Jun. 30, 2023	Mar. 31, 2023
Long-Term Investments [Abstract]
Purchase shares	250,000		64,377
Purchase amount	$ 1,000	$ 80
Additional purchased shares		150,000
Investment		$ 1,080

Long-Term Investments (Details) - Schedule of Long-Term Investments - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	$ 20,922
Long-term investments, Total	23,178	$ 23,103
Investment In Kerna Health Inc [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	2,140
Long-term investments, Total	4,940	4,940
Investment in Kaya Now [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,500
Long-term investments, Total
Investment in Tevva Motors [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,972
Long-term investments, Total	2,794	2,794
Investment in ASP Isotopes [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,300
Long-term investments, Total
Investment in AerocarveUS Corporation [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,075
Long-term investments, Total	1,075	1,000
Investment in Qxpress [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,000
Long-term investments, Total	1,000	1,000
Investment in Masterclass [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	170
Long-term investments, Total	170	170
Investment in Kraken [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	597
Long-term investments, Total	597	597
Investment in Epic Games [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	3,500
Long-term investments, Total	3,500	3,500
Investment in Tesspay [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,240
Long-term investments, Total	2,500	2,500
Investment in SpaceX [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	3,500
Long-term investments, Total	3,674	3,674
Investment in Databricks [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	1,200
Long-term investments, Total	1,200	1,200
Investment in Discord [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	476
Long-term investments, Total	476	476
Investment in Thrasio [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	300
Long-term investments, Total	300	300
Investment in Automation Anywhere [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	476
Long-term investments, Total	476	476
Investment in Anduril [Member]
Long-Term Investments (Details) - Schedule of Long-Term Investments [Line Items]
Long-term investments, Cost Basis	476
Long-term investments, Total	$ 476	$ 476

Notes Receivable (Details) - USD ($)	6 Months Ended	12 Months Ended
Notes Receivable (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Notes Receivable (Details) [Line Items]
Principal amount	$ 1,800,000
Accrued interest	250,000
Interest income	100,000
Impairment loss	$ 0
Convergent Therapeutics, Inc. Investment [Member]
Notes Receivable (Details) [Line Items]
Convertible promissory note percentage	8.00%
Promissory note maturity date	Jan. 29, 2023
Principal amount	$ 1,800,000
Convergent Therapeutics, Inc. Investment [Member] \| Notes Payable [Member]
Notes Receivable (Details) [Line Items]
Principal amount	500,000
Raefan Industries LLC Investment [Member]
Notes Receivable (Details) [Line Items]
Interest income receivable	600,000
Unrealized loss	200,000
American Innovative Robotics, LLC Investment [Member]
Notes Receivable (Details) [Line Items]
Interest income	44,000
Impairment charges		$ 500,000
Kaya Now Promissory Note [Member]
Notes Receivable (Details) [Line Items]
Interest income	$ 10,000

Notes Receivable (Details) - Schedule of Notes Receivable $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Convergent Convertible Note - Current [Member]
Notes receivable, at fair value
Maturity Date	Jan. 29, 2023
Stated Interest Rate	8.00%
Principal Amount	$ 1,000
Interest Receivable	199
Fair Value	$ 1,199
Convergent Convertible Note - Non-Current [Member]
Notes receivable, at fair value
Maturity Date	Jan. 29, 2023
Stated Interest Rate	8.00%
Principal Amount	$ 500
Interest Receivable
Fair Value	$ 500
Raefan Industries LLC Investment [Member]
Notes receivable, at fair value
Maturity Date	Dec. 31, 2023
Stated Interest Rate	8.00%
Principal Amount	$ 4,518
Interest Receivable	623
Fair Value	$ 5,141
American Innovative Robotics Investment [Member]
Notes receivable, at fair value
Maturity Date	Apr. 01, 2027
Stated Interest Rate	8.00%
Principal Amount	$ 1,100
Interest Receivable	22
Fair Value	1,122
Notes Receivable, at Fair Value - Current Portion [Member]
Notes receivable, at fair value
Fair Value	6,339
Notes Receivable, at Fair Value - Non-Current Portion [Member]
Notes receivable, at fair value
Fair Value	$ 1,622

Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value Assets and Liabilities - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Marketable securities:
Equities	$ 20,675	$ 7,130
Total marketable securities	20,675	7,130
Short-term investment	13	13
Notes receivable at fair value, current portion	6,339	7,474
Notes receivable at fair value, non-current portion	1,622	1,100
Quoted prices in active markets (Level 1) [Member]
Marketable securities:
Equities	20,675	7,130
Total marketable securities	20,675	7,130
Short-term investment
Notes receivable at fair value, current portion
Notes receivable at fair value, non-current portion
Significant other observable inputs (Level 2) [Member]
Marketable securities:
Equities
Total marketable securities
Short-term investment
Notes receivable at fair value, current portion
Notes receivable at fair value, non-current portion
Significant unobservable inputs (Level 3) [Member]
Marketable securities:
Equities
Total marketable securities
Short-term investment	13	13
Notes receivable at fair value, current portion	6,339	7,474
Notes receivable at fair value, non-current portion	$ 1,622	$ 1,100

Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value on a Recurring Basis - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term investment at December 31, 2022	$ 13
Short-term investment at June 30, 2023	13
Notes receivable at fair value, current portion at December 31, 2022	7,474
Notes receivable at fair value, non-current portion at December 31, 2022	1,100
Collection of principal outstanding	(500)
Note receivable, Convergent Therapeutics, non-current portion	(500)
Unrealized loss on note receivable	(212)
Accrued interest receivable	77
Notes receivable at fair value, current portion at June 30, 2023	6,339
Note receivable, Convergent Therapeutics, non-current portion	500
Accrued interest receivable	22
Notes receivable at fair value, non-current portion at June 30, 2023	$ 1,622

Leases (Details) - USD ($)		6 Months Ended
Leases (Details) - USD ($)	Sep. 23, 2022	Jun. 30, 2023	Jan. 11, 2023
Leases [Abstract]
Lease commencement date, description		The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date).
Rent payment	$ 49,368		$ 12,874
Increase rent amount	$ 51,868	$ 13,502
Lease cost		$ 400,000
Lease term		5 years

Leases (Details) - Schedule of Lease Assets and Liabilities - Operating lease [Member] $ in Thousands	Jun. 30, 2023 USD ($)
Assets:
Operating lease right-of-use-assets	$ 3,530
Liabilities:
Current operating liabilities	353
Long -term operating liabilities	3,259
Total	$ 3,612

Leases (Details) - Schedule of Summarize Quantitative Information about The Company’s Operating Leases	Jun. 30, 2023
Schedule of summarize quantitative information about the company’s operating leases [Abstract]
Weighted-average remaining lease term – operating leases (in years)	7 years
Weighted-average discount rate – operating leases	10.00%

Leases (Details) - Schedule of Lease Expense to Current Period Operations - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Operating leases
Operating lease cost	$ 179	$ 313
Operating lease expense	179	313
Short-term lease rent expense	33	63
Net rent expense	$ 212	$ 376

Leases (Details) - Schedule of Supplemental Cash Flow Information Related To Leases $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Schedule of supplemental cash flow information related to leases [Abstract]
Operating cash flows - operating leases	$ 72
Right-of-use assets obtained in exchange for operating lease liabilities	$ 2,796

Leases (Details) - Schedule of Future Minimum Payments $ in Thousands	Jun. 30, 2023 USD ($)
Schedule of future minimum payments [Member]
Remaining Period Ended December 31, 2023	$ 327
Year Ended December 31, 2024	750
Year Ended December 31, 2025	688
Year Ended December 31, 2026	688
Year Ended December 31, 2027	688
Year Ended December 31, 2028	770
Thereafter	1,166
Total	5,077
Less present value discount	(1,465)
Operating lease liabilities	$ 3,612

Net Loss per Share (Details) - Schedule of Computation of Diluted Loss Per Share - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	475,166	643,404
Convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	34	34
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	444,796	444,796
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	30,336	198,574

Stockholders’ Equity and Convertible Preferred Stock (Details) - USD ($)		1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 06, 2023	Jun. 27, 2023	Jan. 21, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 20, 2023
Stockholders’ Equity and Convertible Preferred Stock (Details) [Line Items]
Shares cancelled (in Shares)	644,499							25,000
Common stock retirement shares	$ 644,499
Granted shares		$ 503,876
Total fair value		2,700,000
Restricted Stock, Value, Shares Issued Net of Tax Withholdings		1,300,000
Share Buyback Program amount			$ 3,000,000
Share repurchased (in Shares)						236,630
Amount of cost						$ 0.9
Price per share (in Dollars per share)				$ 3.97		$ 3.97
Retired shares of treasury stock (in Shares)	644,499
Original cost	$ 3,800,000
Stock-based compensation expense				$ 1,370,000	$ 105,000	$ 1,375,000	$ 105,000
Estimated future stock-based compensation expense						7,000
Over-Allotment Option [Member]
Stockholders’ Equity and Convertible Preferred Stock (Details) [Line Items]
Stock-based compensation expense						8,000	0
Common Stock [Member]
Stockholders’ Equity and Convertible Preferred Stock (Details) [Line Items]
Granted shares		$ 1,033,591
Stock-based compensation expense

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity - Warrant [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Outstanding beginning balance, Warrants		444,796
Outstanding beginning balance, Weighted Average Exercise Price		$ 29.25
Outstanding beginning balance, Total Intrinsic Value
Outstanding beginning balance, Weighted Average Remaining Contractual Life		3 years 2 months 12 days
Outstanding ending balance, Warrants	444,796
Outstanding ending balance, Weighted Average Exercise Price	$ 29.25
Outstanding ending balance, Total Intrinsic Value
Outstanding ending balance, Weighted Average Remaining Contractual Life	2 years 8 months 15 days

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity [Line Items]
Number of Restricted Stock Awards, beginning balance \| shares	8,068
Weighted Average Grant Day Fair Value, beginning balance \| $ / shares	$ 5.64
Number of Restricted Stock Awards, ending balance \| shares
Weighted Average Grant Day Fair Value, ending balance \| $ / shares
Number of Restricted Stock Awards, Granted \| shares	529,715
Weighted Average Grant Day Fair Value, Granted \| $ / shares	$ 2.58
Number of Restricted Stock Awards, Vested \| shares	(537,783)
Weighted Average Grant Day Fair Value, Vested \| $ / shares	$ 2.63

Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity [Line Items]
Outstanding beginning balance, Number of Shares \| shares	31,193
Outstanding beginning balance, Weighted Average Exercise Price \| $ / shares	$ 302.97
Outstanding ending balance, Intrinsic Value \| $
Outstanding beginning balance, Weighted Average Remaining Contractual Life	7 years 10 months 24 days
Outstanding ending balance, Number of Shares \| shares	30,336
Outstanding ending balance, Weighted Average Exercise Price \| $ / shares	$ 36.97
Outstanding ending balance, Intrinsic Value \| $
Outstanding ending balance, Weighted Average Remaining Contractual Life	7 years 7 months 6 days
Number of Shares, Options vested and exercisable \| shares	26,578
Weighted Average Exercise Price, Options vested and exercisable \| $ / shares	$ 41.35
Total Intrinsic Value, Options vested and exercisable \| $
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable	7 years 6 months
Number of Shares, Employee options expired \| shares	(857)
Weighted Average Exercise Price, Employee options expired \| $ / shares	$ 9,719.07

Revenue (Details) - Schedule of Total Revenues Disaggregated By Revenue - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule of total revenues disaggregated by revenue [Abstract]
Underwriting	$ 43		$ 43
Commissions	14		14
Other	14		14
Total	$ 71		$ 71

Regulatory (Details) $ in Millions	Jun. 30, 2023 USD ($)
Regulatory (Details) [Line Items]
Net capital amount	$ 0.1
Excess amount	7.2
Dominari Securities [Member]
Regulatory (Details) [Line Items]
Net capital amount	$ 7.3

Related Party Transaction (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Related Party Transaction [Abstract]
Incurred fees	$ 80	$ 600

Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Dominari Securities [Member]
Segment Reporting Information [Line Items]
Revenue	$ 71	$ 71
Operating Costs
General and administrative	6,957	8,056
Loss from operations	(6,886)	(7,985)
Other (expenses) income
Interest income	44	44
Total other (expenses) income	44	44
Net loss	(6,842)	(7,941)
Legacy AIkido Pharma [Member]
Segment Reporting Information [Line Items]
Revenue
Operating Costs
General and administrative	2,123	4,857
Research and development	2	3
Loss from operations	(2,125)	(4,860)
Other (expenses) income
Other income
Interest income	116	253
Loss on marketable securities	400	335
Unrealized loss on note receivable	(212)	(212)
Total other (expenses) income	304	376
Net loss	(1,821)	(4,484)
Consolidated [Member]
Segment Reporting Information [Line Items]
Revenue	71	71
Operating Costs
General and administrative	9,080	12,913
Research and development	2	3
Loss from operations	(9,011)	(12,845)
Other (expenses) income
Other income
Interest income	160	297
Loss on marketable securities	400	335
Unrealized loss on note receivable	(212)	(212)
Total other (expenses) income	348	420
Net loss	$ (8,663)	$ (12,425)